로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > CD37

CD37

요약

Name:Leukocyte antigen CD37
Target Synonym:CD37,Tetraspanin-26,CD37 Molecule,CD37 Antigen,Tspan-26,TSPAN26,Cell Differentiation Antigen 37,Leukocyte Surface Antigen CD37,Leukocyte Antigen CD37,GP52-40
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Phase 2 Clinical

라이센싱

Project Name Modality Therapeutic Area Indications Stage Right Available
CD37+CD22 CAR-T Cell therapy Oncology/Cancer AML PCC Global

제품 리스트 구매

일부의 생물활성 데이터

CD7-H52D3-SPR
 CD37 SPR

Anti-CD37 antibody (Naratuximab) captured on Protein A Chip can bind Human CD37 Full Length Protein, His,Flag Tag (Cat. No. CD7-H52D3) with an affinity constant of 20.3 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (Routinely tested).

CD7-H52P4-ELISA
 CD37 ELISA

Immobilized Human CD37 Full Length Protein (VLP) (Cat. No. CD7-H52P4) at 5 μg/mL (100 μL/well) can bind Anti-CD37 antibody (Naratuximab), Human IgG1 with a linear range of 0.1-0.8 ng/mL (QC tested).

Synonym Name

CD37,Tspan-26,TSPAN26

Background

Leukocyte antigen CD37 (CD37) is also known as Tetraspanin-26 (Tspan-26) and TSPAN26,which is a member of the transmembrane 4 superfamily or tetraspanin family. Most of these members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. The proteins encoded by CD37 gene mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility. CD37 is a cell surface glycoprotein that is known to complex with integrins and other transmembrane 4 superfamily proteins. CD37 may play a role in T-cell-B-cell interactions.

Clinical and Translational Updates

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Lutetium (177lu) lilotomab satetraxetan 177Lu-DOTA-HH1 Phase 2 Clinical Nordic Nanovector Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
Naratuximab emtansine IMGN-529; K7153A-SMCC-DM1 Phase 2 Clinical Immunogen Inc Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
AGS-67E AGS-67E Phase 1 Clinical Agensys Inc Leukemia, Hairy Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CAR-37 T cell therapy (Massachusetts General Hospital) Phase 1 Clinical Massachusetts General Hospital Lymphoma, B-Cell; Leukemia; Hematologic Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell Details
QLP-31907 QLP-31907; QLP31907; PSB-202 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
anti-CD19 + anti-CD37 bispecific CAR T-cell therapy (Forevertek Biotechnology/Huazhong University of Science and Technology) Clinical Huazhong University Of Science And Technology Lymphoma, Non-Hodgkin Details

This web search service is supported by Google Inc.

totop